Imaging Comparison for Age-Related Macular Degeneration
(COCO-GA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to compare measurements of geographic atrophy (GA) area between several types of imaging, in order to assess accuracy. The main question to answer is which imaging device provides measurements that are most similar to the standard of care device.Participants will be patients of a retina doctor at University Station Eye Clinic with geographic atrophy, and can expect to be in the study for 60-75 minutes.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What safety data exists for imaging methods used in age-related macular degeneration treatment?
The studies provided do not directly address safety data for the imaging methods used in age-related macular degeneration treatment. They focus on comparing the performance and effectiveness of different imaging systems, such as Optos and Clarus, in detecting retinal conditions like diabetic retinopathy and neovascular AMD. No specific safety concerns or adverse effects are mentioned in these studies.12345
Is ultra-widefield imaging safe for humans?
Is the treatment in the trial 'Imaging Comparison for Age-Related Macular Degeneration' a promising treatment?
The treatment in the trial is promising because it uses advanced imaging techniques to better understand and track the progression of age-related macular degeneration. This can help doctors predict how the disease will develop and potentially improve how they manage and treat it in the future.678910
How does this treatment for age-related macular degeneration differ from other treatments?
What data supports the idea that Imaging Comparison for Age-Related Macular Degeneration is an effective treatment?
The available research shows that the Clarus and Optos imaging systems are effective in detecting neovascular age-related macular degeneration (AMD) when compared to conventional digital fundus photographs. This suggests that these imaging methods can help in the early detection and management of AMD, which is crucial for effective treatment. While the studies also discuss the use of these imaging systems for diabetic retinopathy, the focus on AMD indicates their effectiveness in this specific condition.123411
What data supports the effectiveness of this treatment for age-related macular degeneration?
Who Is on the Research Team?
Amitha Domalpally, MD, PhD
Principal Investigator
University of Wisconsin, Madison
Are You a Good Fit for This Trial?
This trial is for individuals over 50 with a specific eye condition called geographic atrophy due to age-related macular degeneration. Participants should have GA areas between 1.25 and 23 mm², which can be either subfoveal or extrafoveal. Those with neovascular AMD, other retinal diseases that could affect the study, or who cannot undergo eye imaging are not eligible.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo dilated fundus exam and imaging using Optos and Zeiss Clarus ultrawide field FAF, as well as Spectralis AF imaging
Follow-up
Participants are monitored for any immediate reactions post-imaging and data is analyzed
What Are the Treatments Tested in This Trial?
Interventions
- Optos imaging
- Spectralis FAF imaging
- Zeiss Clarus 700 imaging
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Wisconsin, Madison
Lead Sponsor